Jade Biosciences (NASDAQ:JBIO) Shares Gap Up – What’s Next?

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO) gapped up prior to trading on Thursday . The stock had previously closed at $22.55, but opened at $23.82. Jade Biosciences shares last traded at $21.5780, with a volume of 37,273 shares traded.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Jefferies Financial Group reissued a “buy” rating and set a $48.00 price objective on shares of Jade Biosciences in a report on Tuesday, August 11th. HC Wainwright lifted their price target on shares of Jade Biosciences from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. UBS Group assumed coverage on shares of Jade Biosciences in a research note on Monday, June 15th. They set a “buy” rating and a $45.00 price target for the company. Wedbush increased their price objective on shares of Jade Biosciences from $45.00 to $47.00 and gave the company an “outperform” rating in a report on Monday, August 10th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $47.00 price objective on shares of Jade Biosciences in a research note on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.75.

Jade Biosciences Stock Down 5.7%

The business has a fifty day moving average of $20.71 and a 200 day moving average of $18.93. The firm has a market cap of $1.35 billion, a P/E ratio of -11.08 and a beta of 1.49.

Jade Biosciences (NASDAQ:JBIO) last posted its earnings results on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, sell-side analysts expect that Jade Biosciences, Inc. will post -2.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Jade Biosciences

Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its position in shares of Jade Biosciences by 94.0% during the first quarter. Renaissance Technologies LLC now owns 135,039 shares of the company’s stock worth $1,897,000 after purchasing an additional 65,438 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Jade Biosciences in the 1st quarter valued at $43,557,000. Stempoint Capital LP acquired a new stake in Jade Biosciences during the 1st quarter worth $2,164,000. Baker BROS. Advisors LP acquired a new stake in Jade Biosciences during the 4th quarter worth $25,323,000. Finally, Avidity Partners Management LP lifted its holdings in Jade Biosciences by 24.3% during the fourth quarter. Avidity Partners Management LP now owns 1,400,708 shares of the company’s stock worth $21,613,000 after acquiring an additional 273,522 shares in the last quarter.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.